Education
About Us
Working with TipRanks
Follow Us
Werewolf Therapeutics (HOWL)
NASDAQ:HOWL
HOWL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.60 - $4.18
Previous CloseN/A
Volume113.58K
Average Volume (3M)542.20K
Market Cap
$48.01M
Enterprise Value-$55.46M
Total Cash (Recent Filing)$92.93M
Total Debt (Recent Filing)$10.43M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Aug 07, 2025EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding44,873,646
10 Day Avg. Volume663,642
30 Day Avg. Volume542,201
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)0.48
Price to Sales (P/S)0.00
P/FCF Ratio-1.34
Enterprise Value/Market Cap-1.16
Enterprise Value/Revenue-3.53
Enterprise Value/Gross Profit-80.49
Enterprise Value/Ebitda0.25
Forecast
1Y Price Target
$7.00Price Target Upside548.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Werewolf Therapeutics News
PremiumCompany Announcements
Werewolf Therapeutics Adopts New Bylaws and Elects Directors
PremiumCompany Announcements
Werewolf Therapeutics Receives Nasdaq Deficiency Notice
PremiumCompany Announcements
Werewolf Therapeutics Reports Q1 2025 Financial Results
Bulls Say, Bears Say
Bulls Say
Clinical ProgressWTX-330 demonstrated the first-ever monotherapy IL-12 activity at tolerable doses, with stable disease seen in MSS CRC and PDAC, and a PR in anti–PD-1-experienced melanoma.
Financial StabilityThe company ended the quarter with approximately $122.8 million in cash, expected to fund operations until 2Q26, indicating strong financial stability.
Strategic ExpansionWerewolf's strategic expansion of their PREDATOR masking platform to CD3 T-cell engagers is supported by robust clinical validation and industry interest.
Bears Say
Development UncertaintyThere is uncertainty whether the outcomes of WTX-124’s monotherapy and combination trials will be robust enough to engage an investor base generally disinterested in novel cytokine programs.
Nascent Development StageIt is unlikely that the new strategic direction with TCE platform will result in significant appreciation for HOWL in the near-term due to its nascent development stage.
Revenue ConcernsWerewolf reported no revenues for 4Q24 as expected, and R&D expenses were higher than estimated.
Options Prices
Currently, No data available
---
Ownership Overview
27.83%
Insiders
5.22% Mutual Funds
42.46% Other Institutional Investors
18.71% Public Companies and Individual Investors
HOWL FAQ
What was Werewolf Therapeutics’s price range in the past 12 months?
Werewolf Therapeutics lowest stock price was $0.59 and its highest was $4.18 in the past 12 months.
What is Werewolf Therapeutics’s market cap?
Werewolf Therapeutics’s market cap is $48.01M.
When is Werewolf Therapeutics’s upcoming earnings report date?
Werewolf Therapeutics’s upcoming earnings report date is Aug 07, 2025 which is in 25 days.
How were Werewolf Therapeutics’s earnings last quarter?
Werewolf Therapeutics released its earnings results on May 08, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.395 by -$0.005.
Is Werewolf Therapeutics overvalued?
According to Wall Street analysts Werewolf Therapeutics’s price is currently Undervalued.
Does Werewolf Therapeutics pay dividends?
Werewolf Therapeutics does not currently pay dividends.
What is Werewolf Therapeutics’s EPS estimate?
Werewolf Therapeutics’s EPS estimate is -0.47.
How many shares outstanding does Werewolf Therapeutics have?
Werewolf Therapeutics has 44,873,646 shares outstanding.
What happened to Werewolf Therapeutics’s price movement after its last earnings report?
Werewolf Therapeutics reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.395. Following the earnings report the stock price went down -5.435%.
Which hedge fund is a major shareholder of Werewolf Therapeutics?
Currently, no hedge funds are holding shares in HOWL
Werewolf Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (548.15% Upside)
$7.00 (548.15% Upside)
Blogger Sentiment
Bullish
HOWL Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $487.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.90%
12-Months-Change
Fundamentals
Return on Equity
-82.81%
Trailing 12-Months
Asset Growth
-39.62%
Trailing 12-Months
Company Description
Werewolf Therapeutics
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
HOWL Stock 12 Month Forecast
Average Price Target
$7.00
▲(548.15%Upside)
Technical Analysis
Karyopharm Therapeutics
―
Atara Biotherapeutics
―
X4 Pharmaceuticals
―
NRX Pharmaceuticals
―
CAMP4 Therapeutics Corporation
―